Apellis Pharmaceuticals, Inc. 4

Timothy Eugene Sullivan, CFO of Apellis Pharmaceuticals, Inc., transferred 11,096 shares of common stock to an irrevocable trust in a non-market, no‑price transaction.

On April 17, 2026, Timothy Eugene Sullivan, Chief Financial Officer of Apellis Pharmaceuticals, Inc., executed an intra-family estate-planning transfer of 11,096 shares of Apellis common stock from his direct holdings to The Timothy E Sullivan Irrevocable Trust of 2023, reported as a non-market, no‑price transaction under code “G.” Following the transfer, Sullivan’s direct ownership decreased to 140,945 shares, while 71,492 shares are reported as indirectly owned by the irrevocable trust, over which he disclaims beneficial ownership except to the extent of any pecuniary interest. As there was no sale or purchase and no transaction price disclosed, this filing reflects a change in the form of beneficial ownership rather than an economic trade in the open market.

Filing Facts

CIK

1492422

Ticker

APLS

Form

4

Source Type

sec

Accession

0001193125-26-163917

Alert Tier

4